Despite attempting to commercialise its “wheeze test” for asthma for more than 10 years, it has yet to commercialise a product and reported the grand sum of $1000 in cash receipts for the three months to March 31. (Last March it did receive clearance from the US regulator, the FDA, to market and sell its patented Wheezo app, so maybe revenue will pick up.)
Its management team has also had a takeover bid for rival digital health micro-cap business Adherium knocked back on the basis it’s opportunistic and offers Respiri shares, rather than cash.
We can hardly blame Adherium’s shareholders for wanting to be paid in cash.
ADR Price at posting:
1.6¢ Sentiment: Buy Disclosure: Held
